JariwalaĬhapter 22 Vaccines Linked to Chemotherapy: A New Approach to Control Helminth Infections (pages 357–375): Sara Lustigman, James H. Bethony, Maria Victoria Periago and Amar R. Caffrey, Jurg Utzinger and Jennifer KeiserĬhapter 21 Barefoot thru' the Valley of Darkness: Preclinical Development of a Human Hookworm Vaccine (pages 341–356): Jeffrey M. ConderĬhapter 19 Praziquantel: Too Good to be Replaced? (pages 309–321): Livia Pica?Mattoccia and Donato CioliĬhapter 20 Drug Discovery for Trematodiases: Challenges and Progress (pages 323–339): Conor R.
AroianĬhapter 17 Monepantel: From Discovery to Mode of Action (pages 283–296): Ronald Kaminsky and Lucien RufenerĬhapter 18 Discovery, Mode of Action, and Commercialization of Derquantel (pages 297–307): Debra J. SlatkoĬhapter 16 Promise of Bacillus thuringiensis Crystal Proteins as Anthelmintics (pages 267–281): Yan Hu and Raffi V. Taylor, Louise Ford, Achim Hoerauf, Ken Pfarr, Jeremy M.
MartinĬhapter 15 Drugs and Targets to Perturb the Symbiosis of Wolbachia and Filarial Nematodes (pages 251–265): Mark J. Wolstenholme, Cedric Neveu, Jacques Cabaret, Claude L. de Hostos and Tue NguyenĬhapter 14 Antinematodal Drugs – Modes of Action and Resistance: And Worms Will Not Come to Thee (Shakespeare: Cymbeline: IV, ii) (pages 233–249): Alan P. RoyĬhapter 13 Anthelmintic Drugs: Tools and Shortcuts for the Long Road from Discovery to Product (pages 217–232): Eugenio L. HammerlandĬhapter 12 To Kill a Mocking Worm: Strategies to Improve Caenorhabditis elegans as a Model System for use in Anthelmintic Discovery (pages 201–216): Andrew R. Cozzie, Bakela Nare, Kerrie Powell, Ann E. SelzerĬhapter 10 Quantitative High?Content Screening?Based Drug Discovery against Helmintic Diseases (pages 159–179): Rahul SinghĬhapter 11 Use of Rodent Models in the Discovery of Novel Anthelmintics (pages 181–199): Rebecca Fankhauser, Linsey R. GearyĬhapter 9 Identification and Profiling of Nematicidal Compounds in Veterinary Parasitology (pages 135–157): Andreas Rohwer, Jurgen Lutz, Christophe Chassaing, Manfred Uphoff, Anja R. SkellyĬhapter 8 Mechanism?Based Screening Strategies for Anthelmintic Discovery (pages 121–134): Timothy G. GasserĬhapter 6 RNA Interference: A Potential Discovery Tool for Therapeutic Targets of Parasitic Nematodes (pages 89–103): Collette BrittonĬhapter 7 RNA Interference as a Tool for Drug Discovery in Parasitic Flatworms (pages 105–119): Akram A. GasserĬhapter 5 Harnessing Genomic Technologies to Explore the Molecular Biology of Liver Flukes?Major Implications for Fundamental and Applied Research (pages 73–87): Neil D. Roos and Fernan AgueroĬhapter 4 Recent Progress in Transcriptomics of Key Gastrointestinal Nematodes of Animals – Fundamental Research Toward New Intervention Strategies (pages 61–72): Cinzia Cantacessi, Bronwyn E. WalkerĬhapter 3 Integrating and Mining Helminth Genomes to Discover and Prioritize Novel Therapeutic Targets (pages 43–59): Dhanasekaran Shanmugam, Stuart A. With its well-balanced mix of high-profile contributors from academia and industry, this handbook and reference will appeal to a wide audience, including parasitologists, pharmaceutical industry, epidemiologists, and veterinary scientists.Content:Ĭhapter 1 Ligand?Gated Ion Channels as Targets for Anthelmintic Drugs: Past, Current, and Future Perspectives (pages 1–21): Kristin Lees, Ann Sluder, Niroda Shannan, Lance Hammerland and David SattelleĬhapter 2 How Relevant is Caenorhabditis elegans as a Model for the Analysis of Parasitic Nematode Biology? (pages 23–41): Lindy Holden?Dye and Robert J. The result is a broad overview of different drug target evaluation methods, including specific examples of successful drug development against helminthes, and with a whole section devoted to vaccine development.
#TCEL CODE B1650 SERIES#
This third volume in the successful 'Drug Discovery in Infectious Diseases' series is the first to deal with drug discovery in helminthic infections in human and animals.
0 kommentar(er)
